- Home
- CMPO vs TARS Comparison
CMPO vs TARS Comparison
Compare CMPO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMPO | TARS |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CMPO | TARS |
|---|---|---|
| Price | $19.72 | $79.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $25.50 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 997.5K | 564.9K |
| Earning Date | 11-03-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $160,683,000.00 | ★ $366,100,000.00 |
| Revenue This Year | $12.53 | $147.24 |
| Revenue Next Year | $9.95 | $53.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $9.24 | $38.51 |
| 52 Week High | $26.78 | $85.25 |
Technical Indicators
Market Signals| Indicator | CMPO | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 49.91 |
| Support Level | $18.38 | $76.34 |
| Resistance Level | $19.59 | $83.94 |
| Average True Range (ATR) | 0.56 | 2.99 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 84.55 | 43.86 |
Price Performance
Historical ComparisonAbout CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.